Your browser doesn't support javascript.
loading
Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib.
Cetin, Bulent; Gonul, Ipek Isik; Gumusay, Ozge; Afsar, Baris; Bilgetekin, Irem; Ozet, Ahmet; Uner, Aytug.
Afiliação
  • Cetin B; Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
  • Gonul II; Department of Pathology, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Gumusay O; Department of Internal Medicine, Division of Medical Oncology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Tokat, Turkey.
  • Afsar B; Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey.
  • Bilgetekin I; Department of Internal Medicine, Division of Medical Oncology, Dr. A. Y. Ankara Oncology Training and Research Hospital, Ankara, Turkey.
  • Ozet A; Department of Internal Medicine, Division of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Uner A; Department of Internal Medicine, Division of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
J Cancer Res Ther ; 17(2): 408-413, 2021.
Article em En | MEDLINE | ID: mdl-34121685
OBJECTIVE: Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study evaluates ezrin expression in sunitinib-treated metastatic clear cell renal cell carcinoma (ccRCC) patients and elucidates its role as a possible marker for survival. MATERIALS AND METHODS: The expression of ezrin was measured by immunohistochemistry in 80 patients with ccRCC treated by first-line sunitinib between January 2007 and June 2012. Kaplan-Meier curves and log-rank tests were used for analysis of progression-free survival and overall survival (OS), and a multivariate Cox proportional hazard model was employed to identify factors with an independent effect on the survival. RESULTS: In multivariate analysis, liver metastasis (P = 0.018; hazard ratio [HR]: 3.707 (1.257-10.931) and overexpression of ezrin (P = 0.006; HR: 2.993 (1.373-6.523 95% confidence interval) were remained significant factors influencing OS. Overexpression of ezrin in the patients who had progressed in the first 3 months was higher than in the patients who had progressed after 3 months (P = 0.003). The median OS was longer in patients with low levels of ezrin expression (27 months) compared to patients overexpressing ezrin (12 months) (P = 0.001). CONCLUSION: This is the first study in the literature showing that ezrin status is related with prognosis in patients with metastatic ccRCC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Proteínas do Citoesqueleto / Sunitinibe / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Proteínas do Citoesqueleto / Sunitinibe / Neoplasias Renais Tipo de estudo: Observational_studies / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article